He Xinyu, Xu Shengjun, Tang Linsong, Ling Sunbin, Wei Xuyong, Xu Xiao
The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University.
Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province.
Int J Surg. 2024 Jan 1;110(1):406-418. doi: 10.1097/JS9.0000000000000806.
Research on liver transplantation (LT) for liver cancer has gained increasing attention. This paper has comprehensively described the current status, hotspots and trends in this field. A total of 2991 relevant articles from 1 January 1963 to 28 February 2023 were obtained from the Web of Science Core Collection. VOSviewer and CiteSpace software were utilized as bibliometric tools to analyze and visualize knowledge mapping. Between 1963 and 2023, the number of papers in the area of LT for liver cancer increased continuously. A total of 70 countries/regions, 2303 institutions and 14 840 researchers have published research articles, with the United States and China being the two most productive countries. Our bibliometric-based visual analysis revealed the expansion of LT indications for liver cancer and the prevention/treatment of cancer recurrence as ongoing research hotspots over the past decades. Meanwhile, emerging studies also focus on downstaging/bridging treatments before LT and the long-term survival of LT recipient, in particular the precise application of immunosuppressants.
肝癌肝移植(LT)的研究日益受到关注。本文全面阐述了该领域的现状、热点及趋势。从科学网核心合集获取了1963年1月1日至2023年2月28日期间的2991篇相关文章。使用VOSviewer和CiteSpace软件作为文献计量工具来分析和可视化知识图谱。1963年至2023年期间,肝癌肝移植领域的论文数量持续增加。共有70个国家/地区、2303个机构和14840名研究人员发表了研究文章,美国和中国是发文量最高的两个国家。我们基于文献计量的可视化分析表明,肝癌肝移植适应证的扩展以及癌症复发的预防/治疗是过去几十年持续的研究热点。与此同时,新兴研究也聚焦于肝移植前的降期/桥接治疗以及肝移植受者的长期生存,特别是免疫抑制剂的精准应用。
Front Oncol. 2025-6-30
World Neurosurg. 2024-12
Nanomedicine (Lond). 2024-7-2
Hum Vaccin Immunother. 2025-12
Hum Vaccin Immunother. 2025-12
Drug Des Devel Ther. 2025-6-30
World J Gastrointest Oncol. 2025-2-15